Editas Medicine, Inc.

Healthcare · Biotechnology · United States

Last price 2.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 410.06M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ...